Instem plc Centrus Contract Win (5017S)
December 03 2012 - 2:00AM
UK Regulatory
TIDMINS
RNS Number : 5017S
Instem plc
03 December 2012
03 December 2012
Embargoed for 07:00
Instem plc
("Instem", the "Company" or the "Group")
Centrus Contract Win with Top 10 Pharma
Leading Global Biopharmaceutical Company Purchases Instem's
Centrus Software to Convert, Create and Share Research Study
Data
Instem plc (AIM: INS), a leading provider of IT solutions to the
global early development healthcare market, announces today that it
has signed a contract with one of the world's largest
biopharmaceutical organisations. The customer has purchased
multiple modules of the Centrus software suite supporting the
Standard for Exchange of Nonclinical Data (SEND). This six-figure
US Dollar order is the most comprehensive suite of Centrus modules
purchased to date.
Instem's software will be used to reduce time and effort by
translating study data to controlled terminology and automatically
checking against SEND guidelines to ensure compliance. Additionally
it includes the capability for the management, secure storage and
sharing of SEND datasets with external partners.
The SEND standard, named by the US Food & Drug
Administration ("FDA") as the preferred standard for electronic
study submissions, is expected to revolutionise the process for
both pharmaceutical companies and regulators. Currently, FDA
reviewers receive paper or electronic paper submissions, which
require time-consuming manual data input. The SEND format enables
electronic submissions of nonclinical data, thereby improving
efficiency as well as data quality, accessibility and
predictability.
Instem has been an industry leader in SEND since 2004, and has
been an active contributing member to several committees dedicated
to advancing and promoting the standard alongside the US Food &
Drug Administration (FDA). The Group's leading position in this
developing area was underlined in February 2012, when Instem was
recognised for its outstanding contributions to SEND at the
Interchange North America event organised by CDISC, the Clinical
Data Interchange Standards Consortium.
This order is one of a number of contracts currently under
negotiation which have a possibility of closure before the year
end. Some of these are required to meet revenue and profit
expectations for the year. Instem expects to update on trading
prior to closing the financial year ending 31 December 2012.
Phil Reason, CEO of Instem plc, commented: "I am delighted to
announce this contract with one of the largest international
biopharmaceutical companies for our innovative Centrus suite. This
customer is at the forefront of developing SEND for regulatory
submission as well as facilitating the aggregation of internally
and externally generated study data to improve early development
productivity. Given our central position in the development of the
SEND standard and our established global Provantis customer base,
we believe future opportunities for Centrus to be significant."
For further information, please contact:
Instem plc +44 (0) 1785 825 600
Phil Reason, CEO
Nigel Goldsmith, CFO
N+1 Singer (Nominated Adviser &
Broker) +44 (0) 20 3205 7500
Aubrey Powell
Joe Stroud
Newgate Threadneedle +44 (0) 20 7653 9850
Caroline Evans-Jones
Fiona Conroy
About Instem plc
Instem is a leading supplier of IT solutions to the early
development healthcare market. Instem's pre-clinical study
management solutions accelerate drug and chemical development by
increasing productivity, automating processes and enhancing
practices that lead to safer and more effective drugs.
Instem has over 130 customers in North America, Europe, China,
India and Japan, including 16 of the top 20 pharmaceutical and
biotech companies such as GlaxoSmithKline and AstraZeneca. The
Group employs over 110 people in seven offices in the US, UK, China
and India; and has a full service distributor in Japan. It is
estimated that approximately half of the world's pre-clinical drug
safety data has been collected over the last 20 years via Instem
software, making Instem an ideal partner to help unlock the
scientific/commercial value from these legacy repositories.
To learn more about Instem please visit the Company's website,
www.instem.com, or its investor centre
http://investors.instem.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTBMBRTMBMJBPT
Instem (LSE:INS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Instem (LSE:INS)
Historical Stock Chart
From Jul 2023 to Jul 2024